203 related articles for article (PubMed ID: 38491910)
1. Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal-like Breast Cancer.
Zhang J; Miao N; Lao L; Deng W; Wang J; Zhu X; Huang Y; Lin H; Zeng W; Zhang W; Tan L; Yuan X; Zeng X; Zhu J; Chen X; Song E; Yang L; Nie Y; Huang D
Adv Sci (Weinh); 2024 May; 11(20):e2307660. PubMed ID: 38491910
[TBL] [Abstract][Full Text] [Related]
2. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women.
Jing MX; Mao XY; Li C; Wei J; Liu C; Jin F
Tumour Biol; 2011 Aug; 32(4):713-9. PubMed ID: 21625942
[TBL] [Abstract][Full Text] [Related]
4. AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
Liao R; Chen X; Cao Q; Bai L; Ma C; Dai Z; Dong C
Breast Cancer Res; 2024 Apr; 26(1):70. PubMed ID: 38654332
[TBL] [Abstract][Full Text] [Related]
5. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer.
Huang P; Liao R; Chen X; Wu X; Li X; Wang Y; Cao Q; Dong C
Theranostics; 2020; 10(10):4644-4658. PubMed ID: 32292520
[No Abstract] [Full Text] [Related]
6. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.
Shepherd JH; Uray IP; Mazumdar A; Tsimelzon A; Savage M; Hilsenbeck SG; Brown PH
Oncotarget; 2016 Mar; 7(11):13106-21. PubMed ID: 26894864
[TBL] [Abstract][Full Text] [Related]
7. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
8. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
9. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
10. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
11. Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition.
Tang PM; Zhang YY; Xiao J; Tang PC; Chung JY; Li J; Xue VW; Huang XR; Chong CC; Ng CF; Lee TL; To KF; Nikolic-Paterson DJ; Lan HY
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20741-20752. PubMed ID: 32788346
[TBL] [Abstract][Full Text] [Related]
12. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
14. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
15. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A
Breast Cancer Res; 2020 Jun; 22(1):63. PubMed ID: 32527287
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.
Soung YH; Pruitt K; Chung J
Sci Rep; 2014 Jan; 4():3846. PubMed ID: 24457910
[TBL] [Abstract][Full Text] [Related]
18. Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.
Chung S; Jin Y; Han B; Qu Y; Gao B; Giuliano AE; Cui X
Cell Commun Signal; 2017 Jun; 15(1):22. PubMed ID: 28629477
[TBL] [Abstract][Full Text] [Related]
19. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells.
Li Y; Yuan YY; Meeran SM; Tollefsbol TO
Mol Cancer; 2010 Oct; 9():274. PubMed ID: 20946668
[TBL] [Abstract][Full Text] [Related]
20. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
